Skip to main content

2018 | OriginalPaper | Buchkapitel

A Mathematical Model for Tumor–Immune Dynamics in Multiple Myeloma

verfasst von : Jill Gallaher, Kamila Larripa, Urszula Ledzewicz, Marissa Renardy, Blerta Shtylla, Nessy Tania, Diana White, Karen Wood, Li Zhu, Chaitali Passey, Michael Robbins, Natalie Bezman, Suresh Shelat, Hearn Jay Cho, Helen Moore

Erschienen in: Understanding Complex Biological Systems with Mathematics

Verlag: Springer International Publishing

Aktivieren Sie unsere intelligente Suche, um passende Fachinhalte oder Patente zu finden.

search-config
loading …

Abstract

We propose a mathematical model that describes the dynamics of multiple myeloma and three distinct populations of the innate and adaptive immune system: cytotoxic T cells, natural killer cells, and regulatory T cells. The model includes significant biologically- and therapeutically-relevant pathways for inhibitory and stimulatory interactions between these populations. Due to the model complexity, we propose a reduced version that captures the principal biological aspects for advanced disease, while still including potential targets for therapeutic interventions. Analysis of the reduced two-dimensional model revealed details about long-term model behavior. In particular, theoretical results describing equilibria and their associated stability are described in detail. Consistent with the theoretical analysis, numerical results reveal parameter regions for which bistability exits. The two stable states in these cases may correspond to long-term disease control or a higher level of disease burden. This initial analysis of the dynamical system provides a foundation for later work, which will consider combination therapies, their expected outcomes, and optimization of regimens.

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

  • über 102.000 Bücher
  • über 537 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Maschinenbau + Werkstoffe
  • Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Springer Professional "Technik"

Online-Abonnement

Mit Springer Professional "Technik" erhalten Sie Zugriff auf:

  • über 67.000 Bücher
  • über 390 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Maschinenbau + Werkstoffe




 

Jetzt Wissensvorsprung sichern!

Springer Professional "Wirtschaft"

Online-Abonnement

Mit Springer Professional "Wirtschaft" erhalten Sie Zugriff auf:

  • über 67.000 Bücher
  • über 340 Zeitschriften

aus folgenden Fachgebieten:

  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Versicherung + Risiko




Jetzt Wissensvorsprung sichern!

Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat A.K. Abbas, A.H. Lichtman, S. Pillai, Cellular and Molecular Immunology, 8th edn. (Elsevier Saunders, Philadelphia, 2015) A.K. Abbas, A.H. Lichtman, S. Pillai, Cellular and Molecular Immunology, 8th edn. (Elsevier Saunders, Philadelphia, 2015)
2.
Zurück zum Zitat J.C. Arciero, T.L. Jackson, D.E. Kirschner, A mathematical model of tumor-immune evasion and siRNA treatment. Discrete Contin. Dynam. Syst. Ser. B 4(1), 39–58 (2004)MathSciNetMATH J.C. Arciero, T.L. Jackson, D.E. Kirschner, A mathematical model of tumor-immune evasion and siRNA treatment. Discrete Contin. Dynam. Syst. Ser. B 4(1), 39–58 (2004)MathSciNetMATH
3.
Zurück zum Zitat J. Baginska, E. Viry, J. Paggetti, S. Medves, G. Berchem, E. Moussay, B. Janji, The critical role of the tumor microenvironment in shaping natural killer cell-mediated anti-tumor immunity. Front. Immunol. 4, 1–13 (2013)CrossRef J. Baginska, E. Viry, J. Paggetti, S. Medves, G. Berchem, E. Moussay, B. Janji, The critical role of the tumor microenvironment in shaping natural killer cell-mediated anti-tumor immunity. Front. Immunol. 4, 1–13 (2013)CrossRef
4.
Zurück zum Zitat D.M. Benson Jr., C.E. Bakan, A. Mishra, C.C. Hofmeister, Y. Efebera, B. Becknell, R.A. Baiocchi, J. Zhang, J. Yu, M.K. Smith, C.N. Greenfield, P. Porcu, S.M. Devine, R. Rotem-Yehudar, G. Lozanski, J.C. Byrd, M.A. Caligiuri, The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 116(13), 2286–2294 (2010)CrossRef D.M. Benson Jr., C.E. Bakan, A. Mishra, C.C. Hofmeister, Y. Efebera, B. Becknell, R.A. Baiocchi, J. Zhang, J. Yu, M.K. Smith, C.N. Greenfield, P. Porcu, S.M. Devine, R. Rotem-Yehudar, G. Lozanski, J.C. Byrd, M.A. Caligiuri, The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 116(13), 2286–2294 (2010)CrossRef
5.
Zurück zum Zitat F. Bihl, C. Germain, C. Luci, V.M. Braud, Mechanisms of NK cell activation: CD4+ T cells enter the scene. Cell. Mol. Life Sci. 68, 3457–3467 (2011)CrossRef F. Bihl, C. Germain, C. Luci, V.M. Braud, Mechanisms of NK cell activation: CD4+ T cells enter the scene. Cell. Mol. Life Sci. 68, 3457–3467 (2011)CrossRef
6.
Zurück zum Zitat O. Boyman, J. Sprent, The role of interleukin-2 during homeostasis and activation of the immune system. Nat. Rev. Immunol. 12(3), 180 (2012)CrossRef O. Boyman, J. Sprent, The role of interleukin-2 during homeostasis and activation of the immune system. Nat. Rev. Immunol. 12(3), 180 (2012)CrossRef
7.
Zurück zum Zitat W.M.T. Braga, D. Atanackovic, G.W.B. Colleoni, The role of regulatory T cells and TH17 cells in multiple myeloma. Clin. Develop. Immunol. 2012, 293479 (2012)CrossRef W.M.T. Braga, D. Atanackovic, G.W.B. Colleoni, The role of regulatory T cells and TH17 cells in multiple myeloma. Clin. Develop. Immunol. 2012, 293479 (2012)CrossRef
8.
Zurück zum Zitat R.D. Brown, B. Pope, E. Yuen, J. Bibson, D.E. Joshua, The expression of T cell related costimulatory molecules in multiple myeloma. Leuk. Lymphoma 31(3–4), 379–384 (1998)CrossRef R.D. Brown, B. Pope, E. Yuen, J. Bibson, D.E. Joshua, The expression of T cell related costimulatory molecules in multiple myeloma. Leuk. Lymphoma 31(3–4), 379–384 (1998)CrossRef
9.
Zurück zum Zitat E. Carbone, P. Neri, M. Mesuraca, M.T. Fulciniti, T. Otsuki, D. Pende, V. Groh, T. Spies, G. Pollio, D. Cosman, L. Catalano, P. Tassone, B. Rotoli, S. Venuta, HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Immunobiology 105(1), 251–258 (2005) E. Carbone, P. Neri, M. Mesuraca, M.T. Fulciniti, T. Otsuki, D. Pende, V. Groh, T. Spies, G. Pollio, D. Cosman, L. Catalano, P. Tassone, B. Rotoli, S. Venuta, HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Immunobiology 105(1), 251–258 (2005)
10.
Zurück zum Zitat A. Cerwenka, J. Baron, L. Lanier, Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc. Natl. Acad. Sci. 98(20), 11521–11526 (2001)CrossRef A. Cerwenka, J. Baron, L. Lanier, Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc. Natl. Acad. Sci. 98(20), 11521–11526 (2001)CrossRef
11.
Zurück zum Zitat M.-L. Chen, M.J. Pittet, L. Gorelik, R.A. Flavell, R. Weissleder, H. von Boehme, K. Khazaie, Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-β signals in vivo. Proc. Nat. Acad. Sci. 102(2), 419–424 (2005)CrossRef M.-L. Chen, M.J. Pittet, L. Gorelik, R.A. Flavell, R. Weissleder, H. von Boehme, K. Khazaie, Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-β signals in vivo. Proc. Nat. Acad. Sci. 102(2), 419–424 (2005)CrossRef
12.
Zurück zum Zitat A.K. Cooper, P.S. Kim, A cellular automata and a partial differential equation model of tumor-immune dynamics and chemotaxis, in Mathematical Models of Tumor-Immune System Dynamics, ed. by A. Eladaddi, P. Kim, D. Mallet. Springer Proceedings in Mathematics and Statistics, vol. 107 (Springer, New York, 2014), pp. 21–46 A.K. Cooper, P.S. Kim, A cellular automata and a partial differential equation model of tumor-immune dynamics and chemotaxis, in Mathematical Models of Tumor-Immune System Dynamics, ed. by A. Eladaddi, P. Kim, D. Mallet. Springer Proceedings in Mathematics and Statistics, vol. 107 (Springer, New York, 2014), pp. 21–46
13.
Zurück zum Zitat B. Dankbar, T. Padró, R. Leo, B. Feldmann, M. Kropff, R.M. Mesters, H. Serve, W.E. Berdel, J. Kienast, Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. J. Immunol. Res. 95(8), 2630–2636 (2000) B. Dankbar, T. Padró, R. Leo, B. Feldmann, M. Kropff, R.M. Mesters, H. Serve, W.E. Berdel, J. Kienast, Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. J. Immunol. Res. 95(8), 2630–2636 (2000)
14.
Zurück zum Zitat G. D’Arena, G. Rossi, L. Laurenti, T. Statuto, F. D’Auria, L. Valvano, V. Simeon, A. Giudice, I. Innocenti, V. De Feo, R. Filosa, P. Musto, Circulating regulatory T-cells in monoclonal gammopathies of uncertain significance and multiple myeloma: in search of a role. J. Immunol. Res. 2016, 9271469 (2016)CrossRef G. D’Arena, G. Rossi, L. Laurenti, T. Statuto, F. D’Auria, L. Valvano, V. Simeon, A. Giudice, I. Innocenti, V. De Feo, R. Filosa, P. Musto, Circulating regulatory T-cells in monoclonal gammopathies of uncertain significance and multiple myeloma: in search of a role. J. Immunol. Res. 2016, 9271469 (2016)CrossRef
15.
Zurück zum Zitat R.J. de Boer, D. Homann, A.S. Perelson, Different dynamics of CD4+ and CD8+ T cell responses during and after acute lymphocytic choriomeningitis virus infection. J. Immunol. 171(8), 3928–3935 (2003)CrossRef R.J. de Boer, D. Homann, A.S. Perelson, Different dynamics of CD4+ and CD8+ T cell responses during and after acute lymphocytic choriomeningitis virus infection. J. Immunol. 171(8), 3928–3935 (2003)CrossRef
16.
Zurück zum Zitat L.G. de Pillis, A. Radunskaya, C.L. Wiseman, A validated mathematical model of cell-mediated immune response to tumor growth. Cancer Res. 65, 7950–7958 (2005)CrossRef L.G. de Pillis, A. Radunskaya, C.L. Wiseman, A validated mathematical model of cell-mediated immune response to tumor growth. Cancer Res. 65, 7950–7958 (2005)CrossRef
17.
Zurück zum Zitat L. de Pillis, T. Caldwell, E. Sarapata, H. Williams, Mathematical modeling of regulatory T cell effects on renal cell carcinoma treatment. Discrete Contin. Dynam. Syst.-Ser. B 18(4), 915–943 (2013)MathSciNetCrossRef L. de Pillis, T. Caldwell, E. Sarapata, H. Williams, Mathematical modeling of regulatory T cell effects on renal cell carcinoma treatment. Discrete Contin. Dynam. Syst.-Ser. B 18(4), 915–943 (2013)MathSciNetCrossRef
18.
Zurück zum Zitat L. de Pillis, A. Gallegos, A. Radunskaya, A model of dendritic cell therapy for melanoma. Front. Oncol. 3, 56 (2013) L. de Pillis, A. Gallegos, A. Radunskaya, A model of dendritic cell therapy for melanoma. Front. Oncol. 3, 56 (2013)
19.
Zurück zum Zitat H.P. de Vladar, J.A. González, Dynamic response of cancer under the influence of immunological activity and therapy. J. Theor. Biol. 227(3), 335–348 (2004)MathSciNetCrossRef H.P. de Vladar, J.A. González, Dynamic response of cancer under the influence of immunological activity and therapy. J. Theor. Biol. 227(3), 335–348 (2004)MathSciNetCrossRef
20.
Zurück zum Zitat M. Delitalia, T. Lorenzi, M. Melensi, A structured population model of competition between cancer cells and T cells under immunotherapy, in Mathematical Models of Tumor-Immune System Dynamics, ed. by A. Eladaddi, P. Kim, D. Mallet. Springer Proceedings in Mathematics and Statistics, vol. 107 (Springer, New York, 2014), pp. 47–58 M. Delitalia, T. Lorenzi, M. Melensi, A structured population model of competition between cancer cells and T cells under immunotherapy, in Mathematical Models of Tumor-Immune System Dynamics, ed. by A. Eladaddi, P. Kim, D. Mallet. Springer Proceedings in Mathematics and Statistics, vol. 107 (Springer, New York, 2014), pp. 47–58
21.
Zurück zum Zitat M.V. Dhodapkar, M.D. Geller, D.H. Chang, K. Shimizu, S.-I. Fujii, K.M. Dhodapkar, J. Krasovsky, A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J. Exp. Med. 197(12), 1667–1676 (2003)CrossRef M.V. Dhodapkar, M.D. Geller, D.H. Chang, K. Shimizu, S.-I. Fujii, K.M. Dhodapkar, J. Krasovsky, A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J. Exp. Med. 197(12), 1667–1676 (2003)CrossRef
22.
Zurück zum Zitat A. Diefenbach, E.R. Jensen, A.M. Jamieson, D.H. Raulet, Rae1 and H60 ligands of the NKG2D receptor stimulate tumor immunity. Nature 413(6852), 165 (2001)CrossRef A. Diefenbach, E.R. Jensen, A.M. Jamieson, D.H. Raulet, Rae1 and H60 ligands of the NKG2D receptor stimulate tumor immunity. Nature 413(6852), 165 (2001)CrossRef
23.
Zurück zum Zitat R.J. DiPaolo, D.D. Glass, K.E. Bijwaard, E.M. Shevach, CD4+ CD25+ T cells prevent the development of organ-specific autoimmune disease by inhibiting the differentiation of autoreactive effector T cells. J. Immunol. 175(11), 7135–7142 (2005)CrossRef R.J. DiPaolo, D.D. Glass, K.E. Bijwaard, E.M. Shevach, CD4+ CD25+ T cells prevent the development of organ-specific autoimmune disease by inhibiting the differentiation of autoreactive effector T cells. J. Immunol. 175(11), 7135–7142 (2005)CrossRef
24.
Zurück zum Zitat A. d’Onofrio, A general framework for modelling tumor-immune system competition and immunotherapy: mathematical analysis and biomedical inferences. Physica D 208(3–4), 202–235 (2005)MathSciNetMATH A. d’Onofrio, A general framework for modelling tumor-immune system competition and immunotherapy: mathematical analysis and biomedical inferences. Physica D 208(3–4), 202–235 (2005)MathSciNetMATH
25.
Zurück zum Zitat T. Dosani, M. Carlsten, I. Maric, O. Landgren, The cellular immune system in myelomagenesis: NK cells and T cells in the development of MM and their uses in immunotherapies. Blood Cancer J. 5(4), e306 (2015)CrossRef T. Dosani, M. Carlsten, I. Maric, O. Landgren, The cellular immune system in myelomagenesis: NK cells and T cells in the development of MM and their uses in immunotherapies. Blood Cancer J. 5(4), e306 (2015)CrossRef
26.
Zurück zum Zitat B.G.M. Durie, S.E. Salmon, A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36, 842–854 (1975)CrossRef B.G.M. Durie, S.E. Salmon, A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36, 842–854 (1975)CrossRef
27.
Zurück zum Zitat A. Eladaddi, P. Kim, D. Mallet (eds.), Mathematical Models of Tumor-Immune System Dynamics. Springer Proceedings in Mathematics and Statistics, vol. 107 (Springer, New York, 2014) A. Eladaddi, P. Kim, D. Mallet (eds.), Mathematical Models of Tumor-Immune System Dynamics. Springer Proceedings in Mathematics and Statistics, vol. 107 (Springer, New York, 2014)
28.
Zurück zum Zitat J. Favaloro, R. Brown, E. Aklilu, S. Yang, H. Suen, D. Hart, P. Fromm, J. Gibson, L. Khoo, P.J. Ho, D. Joshua, Myeloma skews regulatory T and pro-inflammatory T helper 17 cell balance in favor of a suppressive state. Leuk. Lymphoma 55(5), 1090–1098 (2014)CrossRef J. Favaloro, R. Brown, E. Aklilu, S. Yang, H. Suen, D. Hart, P. Fromm, J. Gibson, L. Khoo, P.J. Ho, D. Joshua, Myeloma skews regulatory T and pro-inflammatory T helper 17 cell balance in favor of a suppressive state. Leuk. Lymphoma 55(5), 1090–1098 (2014)CrossRef
29.
Zurück zum Zitat S. Feyler, M. von Lilienfeld-Toal, S. Jarmin, L. Marles, A. Rawstron, A.J. Ashcroft, R.G. Owen, P.J. Selby, G. Cook, CD4(+)CD25(+)FoxP3(+) regulatory T cells are increased whilst CD3(+)CD4(−)CD8(−)alphabetaTCR(+) double negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden. Br. J. Haematol. 144, 686–695 (2009)CrossRef S. Feyler, M. von Lilienfeld-Toal, S. Jarmin, L. Marles, A. Rawstron, A.J. Ashcroft, R.G. Owen, P.J. Selby, G. Cook, CD4(+)CD25(+)FoxP3(+) regulatory T cells are increased whilst CD3(+)CD4(−)CD8(−)alphabetaTCR(+) double negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden. Br. J. Haematol. 144, 686–695 (2009)CrossRef
30.
Zurück zum Zitat S. Feyler, G.B. Scott, C. Parrish, S. Jarmin, P, Evans, M. Short, K. McKinley, P.J. Selby, G. Cook, Tumour cell generation of inducible regulatory T-cells in multiple myeloma is contact-dependent and antigen-presenting cell-independent. PLoS ONE 7(5), e35981 (2012)CrossRef S. Feyler, G.B. Scott, C. Parrish, S. Jarmin, P, Evans, M. Short, K. McKinley, P.J. Selby, G. Cook, Tumour cell generation of inducible regulatory T-cells in multiple myeloma is contact-dependent and antigen-presenting cell-independent. PLoS ONE 7(5), e35981 (2012)CrossRef
31.
Zurück zum Zitat F. Frascoli, P.S. Kim, B.D. Hughes, K.A. Landman, A dynamical model of tumour immunotherapy. Math. Biosci. 253, 50–62 (2014)MathSciNetCrossRef F. Frascoli, P.S. Kim, B.D. Hughes, K.A. Landman, A dynamical model of tumour immunotherapy. Math. Biosci. 253, 50–62 (2014)MathSciNetCrossRef
32.
Zurück zum Zitat C. Frohn, M. Hoppner, P. Schlenke, H. Kirchner, P. Koritke, J. Luhm, Anti-myeloma activity of natural killer lymphocytes. Br. J. Haematol. 119, 660–664 (2002)CrossRef C. Frohn, M. Hoppner, P. Schlenke, H. Kirchner, P. Koritke, J. Luhm, Anti-myeloma activity of natural killer lymphocytes. Br. J. Haematol. 119, 660–664 (2002)CrossRef
33.
Zurück zum Zitat D.I. Gabrilovich, H.L. Chen, K.R. Girgis, H.T. Cunningham, G.M. Meny, S. Nadaf, D. Kavanaugh, D.P. Carbone, Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 2(10), 1096–1103 (1996)CrossRef D.I. Gabrilovich, H.L. Chen, K.R. Girgis, H.T. Cunningham, G.M. Meny, S. Nadaf, D. Kavanaugh, D.P. Carbone, Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 2(10), 1096–1103 (1996)CrossRef
34.
Zurück zum Zitat M. Gao, L. Gao, G. Yang, Y. Tao, J. Hou, H. Xu, X. Hu, Y. Han, Q. Zhang, F. Zhan, X. Wu, J. Shi, Myeloma cells resistance to NK cell lysis mainly involves an HLA class I-dependent mechanism. Acta Biochim. Biophys. Sin. 46(7), 597–604 (2014)CrossRef M. Gao, L. Gao, G. Yang, Y. Tao, J. Hou, H. Xu, X. Hu, Y. Han, Q. Zhang, F. Zhan, X. Wu, J. Shi, Myeloma cells resistance to NK cell lysis mainly involves an HLA class I-dependent mechanism. Acta Biochim. Biophys. Sin. 46(7), 597–604 (2014)CrossRef
35.
Zurück zum Zitat F. Ghiringhelli, C. Ménard, M. Terme, C. Flament, J. Taieb, N. Chaput, P.E. Puig, S. Novault, B. Escudier, E. Vivier et al. CD4+ CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-β-dependent manner. J. Exp. Med. 202(8), 1075–1085 (2005)CrossRef F. Ghiringhelli, C. Ménard, M. Terme, C. Flament, J. Taieb, N. Chaput, P.E. Puig, S. Novault, B. Escudier, E. Vivier et al. CD4+ CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-β-dependent manner. J. Exp. Med. 202(8), 1075–1085 (2005)CrossRef
36.
Zurück zum Zitat F. Ghiringhelli, C. Ménard, F. Martin, L. Zitvogel, The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression. Immunol. Rev. 214(1), 229–238 (2006)CrossRef F. Ghiringhelli, C. Ménard, F. Martin, L. Zitvogel, The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression. Immunol. Rev. 214(1), 229–238 (2006)CrossRef
37.
Zurück zum Zitat G. Görgün, M.K. Samur, K.B Cowens, S. Paula, G. Bianchi, J.E. Anderson, R.E. White, A. Singh, H. Ohguchi, R. Suzuki, S. Kikuchi, T. Harada, T. Hideshima, Y.-T. Tai, J.P Laubach, N. Raje, F. Magrangeas, S. Minvielle, H. Avet-Loiseau, N.C. Munshi, D.M. Dorfman, P.G Richardson, K.C. Anderson, Lenalidomide enhances immune checkpoint blockade-induced immune response in multiple myeloma. Clin. Cancer Res. 21(20), 4607–4618 (2015)CrossRef G. Görgün, M.K. Samur, K.B Cowens, S. Paula, G. Bianchi, J.E. Anderson, R.E. White, A. Singh, H. Ohguchi, R. Suzuki, S. Kikuchi, T. Harada, T. Hideshima, Y.-T. Tai, J.P Laubach, N. Raje, F. Magrangeas, S. Minvielle, H. Avet-Loiseau, N.C. Munshi, D.M. Dorfman, P.G Richardson, K.C. Anderson, Lenalidomide enhances immune checkpoint blockade-induced immune response in multiple myeloma. Clin. Cancer Res. 21(20), 4607–4618 (2015)CrossRef
38.
Zurück zum Zitat C.T. Hansen, P.T. Pedersen, L.C. Nielsen, N. Abildgaard, Evaluation of the serum free light chain (sFLC) analysis in prediction of response in symptomatic multiple myeloma patients: rapid profound reduction in involved FLC predicts achievement of VGPR. Eur. J. Haematol. 93(5), 407–413 (2014)CrossRef C.T. Hansen, P.T. Pedersen, L.C. Nielsen, N. Abildgaard, Evaluation of the serum free light chain (sFLC) analysis in prediction of response in symptomatic multiple myeloma patients: rapid profound reduction in involved FLC predicts achievement of VGPR. Eur. J. Haematol. 93(5), 407–413 (2014)CrossRef
39.
Zurück zum Zitat C.A. Janeway, How the immune system protects the host from infection. Microbes Infect. 3(13), 1167–1171 (2001)CrossRef C.A. Janeway, How the immune system protects the host from infection. Microbes Infect. 3(13), 1167–1171 (2001)CrossRef
40.
Zurück zum Zitat F. Jonsson, Y. Ou, L. Claret, D. Siegel, S. Jagannath, R. Vij, A. Badros, S. Aggarwal, R. Bruno, A tumor growth inhibition model based on M-protein levels in subjects with relapsed/refractory multiple myeloma following single-agent carfilzomib use. CPT: Pharmacometrics Syst. Pharmacol. 4(12), 711–719 (2015) F. Jonsson, Y. Ou, L. Claret, D. Siegel, S. Jagannath, R. Vij, A. Badros, S. Aggarwal, R. Bruno, A tumor growth inhibition model based on M-protein levels in subjects with relapsed/refractory multiple myeloma following single-agent carfilzomib use. CPT: Pharmacometrics Syst. Pharmacol. 4(12), 711–719 (2015)
41.
Zurück zum Zitat Y. Kawano, M. Moschetta, S. Manier, S. Glavey, G.T. Görgün, A.M. Roccaro, K.C. Anderson, I.M. Ghobrial, Targeting the bone marrow microenvironment in multiple myeloma. Immunol. Rev. 263(1), 160–172 (2015)CrossRef Y. Kawano, M. Moschetta, S. Manier, S. Glavey, G.T. Görgün, A.M. Roccaro, K.C. Anderson, I.M. Ghobrial, Targeting the bone marrow microenvironment in multiple myeloma. Immunol. Rev. 263(1), 160–172 (2015)CrossRef
42.
Zurück zum Zitat Y. Kawarada, R. Ganss, N. Garbi, T. Sacher, B. Arnold, G.J. Hämmerling, NK-and CD8+ T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides. J. Immunol. 167(9), 5247–5253 (2001)CrossRef Y. Kawarada, R. Ganss, N. Garbi, T. Sacher, B. Arnold, G.J. Hämmerling, NK-and CD8+ T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides. J. Immunol. 167(9), 5247–5253 (2001)CrossRef
43.
Zurück zum Zitat D. Kazandjian, O. Landgren, A look backward and forward in the regulatory and treatment history of multiple myeloma: approval of novel-novel agents, new drug development, and longer patient survival. Semin. Oncol. 43, 682–689 (2016)CrossRef D. Kazandjian, O. Landgren, A look backward and forward in the regulatory and treatment history of multiple myeloma: approval of novel-novel agents, new drug development, and longer patient survival. Semin. Oncol. 43, 682–689 (2016)CrossRef
44.
Zurück zum Zitat J.M. Kim, J.P. Rasmussen, A.Y. Rudensky, Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat. Immunol. 8(2), 191 (2007)CrossRef J.M. Kim, J.P. Rasmussen, A.Y. Rudensky, Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat. Immunol. 8(2), 191 (2007)CrossRef
45.
Zurück zum Zitat D. Kirschner, J.C. Panetta, Modeling immunotherapy of the tumor-immune interaction. J. Math. Biol. 37, 235–252 (2007)CrossRef D. Kirschner, J.C. Panetta, Modeling immunotherapy of the tumor-immune interaction. J. Math. Biol. 37, 235–252 (2007)CrossRef
46.
Zurück zum Zitat M. Kocoglu, A. Badros, The role of immunotherapy in multiple myeloma. Pharmaceuticals 9(1), 3 (2016)CrossRef M. Kocoglu, A. Badros, The role of immunotherapy in multiple myeloma. Pharmaceuticals 9(1), 3 (2016)CrossRef
47.
Zurück zum Zitat J. Krejcik, T. Casneuf, I.S. Nijhof, B. Verbist, J. Bald, T. Plesner, K. Syed, K. Liu, N.W.C.J. van de Donk, B.M. Weiss, T. Ahmadi, H.M. Lokhorst, T. Mutis, A.K. Sasser, Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood 128(3), 384–394 (2016)CrossRef J. Krejcik, T. Casneuf, I.S. Nijhof, B. Verbist, J. Bald, T. Plesner, K. Syed, K. Liu, N.W.C.J. van de Donk, B.M. Weiss, T. Ahmadi, H.M. Lokhorst, T. Mutis, A.K. Sasser, Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood 128(3), 384–394 (2016)CrossRef
48.
Zurück zum Zitat V.A. Kuznetsov, I.A. Makalkin, M.A. Taylor, A.S. Perelson, Nonlinear dynamics of immunogenic tumors: parameter estimation and global bifurcation analysis. Bull. Math. Biol. 56(2), 295–321 (1994)CrossRef V.A. Kuznetsov, I.A. Makalkin, M.A. Taylor, A.S. Perelson, Nonlinear dynamics of immunogenic tumors: parameter estimation and global bifurcation analysis. Bull. Math. Biol. 56(2), 295–321 (1994)CrossRef
49.
Zurück zum Zitat R.A. Kyle, T.M. Therneau, S.V. Rajkumar, J.R. Offord, D.R. Larson, M.F. Plevak, L.J. Melton 3rd, A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N. Engl. J. Med. 346(8), 564–569 (2002)CrossRef R.A. Kyle, T.M. Therneau, S.V. Rajkumar, J.R. Offord, D.R. Larson, M.F. Plevak, L.J. Melton 3rd, A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N. Engl. J. Med. 346(8), 564–569 (2002)CrossRef
50.
Zurück zum Zitat R.A. Kyle, M.A. Gertz, T.E. Witzig, J.A. Lust, M.Q. Lacy, A. Dispenzieri, R. Fonseca, S.V. Rajkumar, J.R. Offord, D.R. Larson, M.E. Plevak, T.M. Therneau, P.R. Greipp, Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin. Proc. 78, 21–33 (2003)CrossRef R.A. Kyle, M.A. Gertz, T.E. Witzig, J.A. Lust, M.Q. Lacy, A. Dispenzieri, R. Fonseca, S.V. Rajkumar, J.R. Offord, D.R. Larson, M.E. Plevak, T.M. Therneau, P.R. Greipp, Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin. Proc. 78, 21–33 (2003)CrossRef
51.
Zurück zum Zitat R.A. Kyle, E.D. Remstein, T.M. Therneau, A. Dispenzieri, P.J. Kurtin, J.M. Hodnefield, D.R. Larson, M.F. Plevak, D.F. Jelinek, R. Fonseca, L.J. Melton 3rd, S.V. Rajkumar, Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N. Engl. J. Med. 356(25), 2582–2590 (2007)CrossRef R.A. Kyle, E.D. Remstein, T.M. Therneau, A. Dispenzieri, P.J. Kurtin, J.M. Hodnefield, D.R. Larson, M.F. Plevak, D.F. Jelinek, R. Fonseca, L.J. Melton 3rd, S.V. Rajkumar, Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N. Engl. J. Med. 356(25), 2582–2590 (2007)CrossRef
52.
Zurück zum Zitat U. Ledzewicz, H. Moore, Dynamical systems properties of a mathematical model for the treatment of CML. Appl. Sci. 6, 291 (2016)CrossRef U. Ledzewicz, H. Moore, Dynamical systems properties of a mathematical model for the treatment of CML. Appl. Sci. 6, 291 (2016)CrossRef
53.
Zurück zum Zitat U. Ledzewicz, M. Naghnaeian, H. Schättler, Optimal response to chemotherapy for a mathematical model of tumor-immune dynamics. J. Math. Biol. 64, 557–577 (2012)MathSciNetCrossRef U. Ledzewicz, M. Naghnaeian, H. Schättler, Optimal response to chemotherapy for a mathematical model of tumor-immune dynamics. J. Math. Biol. 64, 557–577 (2012)MathSciNetCrossRef
54.
Zurück zum Zitat C. Lehman, M. Zeis, L. Uharek, Activation of natural killer cells with interleukin 2 (IL-2) and IL-12 increases perforin binding and subsequent lysis of tumour cells. Br. J. Haematol. 114(3), 660–665 (2001)CrossRef C. Lehman, M. Zeis, L. Uharek, Activation of natural killer cells with interleukin 2 (IL-2) and IL-12 increases perforin binding and subsequent lysis of tumour cells. Br. J. Haematol. 114(3), 660–665 (2001)CrossRef
55.
Zurück zum Zitat K.-L. Liao, X.-F. Bai, A. Friedman, Mathematical modeling of interleukin-27 induction of anti-tumor T cells response. PLoS ONE 9(3), e91844 (2014)CrossRef K.-L. Liao, X.-F. Bai, A. Friedman, Mathematical modeling of interleukin-27 induction of anti-tumor T cells response. PLoS ONE 9(3), e91844 (2014)CrossRef
56.
Zurück zum Zitat A. Maniatis, Pathophysiology of paraprotein production. Ren. Fail. 20(6), 821–828 (1998)CrossRef A. Maniatis, Pathophysiology of paraprotein production. Ren. Fail. 20(6), 821–828 (1998)CrossRef
57.
Zurück zum Zitat T.R. Mempel, M.J. Pittet, K. Khazaie, W. Weninger, R. Weissleder, H. von Boehmer, U.H. von Andrian, Regulatory T cells reversibly suppress cytotoxic T cell function independent of effector differentiation. Immunity 25(1), 129–141 (2006)CrossRef T.R. Mempel, M.J. Pittet, K. Khazaie, W. Weninger, R. Weissleder, H. von Boehmer, U.H. von Andrian, Regulatory T cells reversibly suppress cytotoxic T cell function independent of effector differentiation. Immunity 25(1), 129–141 (2006)CrossRef
58.
Zurück zum Zitat N.J. Meropol, G.M. Barresi, T.A. Fehniger, J. Hitt, M. Franklin, M.A. Caligiuri, Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing. Cancer Immunol. Immunother. 46(6), 318–326 (1998)CrossRef N.J. Meropol, G.M. Barresi, T.A. Fehniger, J. Hitt, M. Franklin, M.A. Caligiuri, Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing. Cancer Immunol. Immunother. 46(6), 318–326 (1998)CrossRef
59.
Zurück zum Zitat A.J. Michielsen, A.E. Hogan, J. Marry, M. Tosetto, F. Cox, J.M. Hyland, K.D. Sheahan, D.P. O’Donoghue, H.E. Mulcahy, E.J. Ryan, J.N. O’Sullivan, Tumour tissue microenvironment can inhibit dendritic cell maturation in colorectal cancer. PLoS ONE 6(11), e27944 (2011)CrossRef A.J. Michielsen, A.E. Hogan, J. Marry, M. Tosetto, F. Cox, J.M. Hyland, K.D. Sheahan, D.P. O’Donoghue, H.E. Mulcahy, E.J. Ryan, J.N. O’Sullivan, Tumour tissue microenvironment can inhibit dendritic cell maturation in colorectal cancer. PLoS ONE 6(11), e27944 (2011)CrossRef
60.
Zurück zum Zitat J.R. Mills, D.R. Barnidge, A. Dispenzieri, D.L. Murray, High sensitivity blood-based M-protein detection in sCR patients with multiple myeloma. Blood Cancer J. 7(8), e590 (2017)CrossRef J.R. Mills, D.R. Barnidge, A. Dispenzieri, D.L. Murray, High sensitivity blood-based M-protein detection in sCR patients with multiple myeloma. Blood Cancer J. 7(8), e590 (2017)CrossRef
61.
Zurück zum Zitat H. Moore, N.K. Li, A mathematical model for chronic myelogenous leukemia (CML) and T cell interaction. J. Theor. Biol. 227(4), 513–523 (2004)MathSciNetCrossRef H. Moore, N.K. Li, A mathematical model for chronic myelogenous leukemia (CML) and T cell interaction. J. Theor. Biol. 227(4), 513–523 (2004)MathSciNetCrossRef
62.
Zurück zum Zitat S. Nanda, H. Moore, S. Lenhart, Optimal control of treatment in a mathematical model of chronic myelogenous leukemia. Math. Biosci. 210(1), 143–156 (2007)MathSciNetCrossRef S. Nanda, H. Moore, S. Lenhart, Optimal control of treatment in a mathematical model of chronic myelogenous leukemia. Math. Biosci. 210(1), 143–156 (2007)MathSciNetCrossRef
63.
Zurück zum Zitat T.X. O’Connell, T.J. Horita, B. Kasravi, Understanding and interpreting serum protein electrophoresis. Am. Fam. Physician 71(1), 105–112 (2005) T.X. O’Connell, T.J. Horita, B. Kasravi, Understanding and interpreting serum protein electrophoresis. Am. Fam. Physician 71(1), 105–112 (2005)
64.
Zurück zum Zitat T.M. Oivanen, Plateau phase in multiple myeloma: an analysis of long-term follow-up of 432 patients. Br. J. Haematol. 92(4), 834–839 (1996)CrossRef T.M. Oivanen, Plateau phase in multiple myeloma: an analysis of long-term follow-up of 432 patients. Br. J. Haematol. 92(4), 834–839 (1996)CrossRef
65.
Zurück zum Zitat K. Pallmer, A. Oxenius, Recognition and regulation of T cells by NK cells. Front. Immunol. 7, 251 (2016)CrossRef K. Pallmer, A. Oxenius, Recognition and regulation of T cells by NK cells. Front. Immunol. 7, 251 (2016)CrossRef
66.
Zurück zum Zitat D.M. Pardoll, The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252–264 (2012)CrossRef D.M. Pardoll, The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252–264 (2012)CrossRef
67.
Zurück zum Zitat T. Pazina, A.M. James, A.W. MacFarlane IV, N.A. Bezman, K.A. Henning, C. Bee, R.F. Graziano, M.D. Robbins, A.D Cohen, K.S. Campbell, The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and independent mechanisms. OncoImmunology 6(9), e1339853 (2017)CrossRef T. Pazina, A.M. James, A.W. MacFarlane IV, N.A. Bezman, K.A. Henning, C. Bee, R.F. Graziano, M.D. Robbins, A.D Cohen, K.S. Campbell, The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and independent mechanisms. OncoImmunology 6(9), e1339853 (2017)CrossRef
68.
Zurück zum Zitat R.J. Pessoa de Magalhães, M.-B. Vidriales, B. Paiva, C. Fernandez-Gimenez, R. García-Sanz, M.-V. Mateos, N.C. Gutierrez, Q. Lecrevisse, J.F. Blanco, J. Hernández, N. de las Heras, J. Martinez-Lopez, M. Roig, E.S. Costa, E.M. Ocio, M. Perez-Andres, A. Maiolino, M. Nucci, J. De La Rubia, J.-J. Lahuerta, J.F. San-Miguel, A. Orfao, Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry. Haematologica 98(1), 79–86 (2013)CrossRef R.J. Pessoa de Magalhães, M.-B. Vidriales, B. Paiva, C. Fernandez-Gimenez, R. García-Sanz, M.-V. Mateos, N.C. Gutierrez, Q. Lecrevisse, J.F. Blanco, J. Hernández, N. de las Heras, J. Martinez-Lopez, M. Roig, E.S. Costa, E.M. Ocio, M. Perez-Andres, A. Maiolino, M. Nucci, J. De La Rubia, J.-J. Lahuerta, J.F. San-Miguel, A. Orfao, Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry. Haematologica 98(1), 79–86 (2013)CrossRef
69.
Zurück zum Zitat G. Pratt, O. Goodyear, P. Moss, Immunodeficiency and immunotherapy in multiple myeloma. Br. J. Haematol. 138, 563–579 (2007)CrossRef G. Pratt, O. Goodyear, P. Moss, Immunodeficiency and immunotherapy in multiple myeloma. Br. J. Haematol. 138, 563–579 (2007)CrossRef
70.
Zurück zum Zitat M. Raitakari, R.D. Brown, J. Gibson, D.E. Joshua, T cells in myeloma. Hematol. Oncol. 21(1), 33–42 (2003)CrossRef M. Raitakari, R.D. Brown, J. Gibson, D.E. Joshua, T cells in myeloma. Hematol. Oncol. 21(1), 33–42 (2003)CrossRef
71.
Zurück zum Zitat K.R.M. Raja, L. Rihova, L. Zahradova, M. Klincova, M. Penka, R. Hajek, Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma. PLoS ONE 7(10), e47077 (2012) K.R.M. Raja, L. Rihova, L. Zahradova, M. Klincova, M. Penka, R. Hajek, Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma. PLoS ONE 7(10), e47077 (2012)
72.
Zurück zum Zitat M. Ratta, F. Fagnoni, A. Curti, R. Vescovini, P. Sansoni, B. Oliviero, M. Fogli, E. Ferri, G. Robustelli Della Cuna, S. Tura, M. Baccarani, R.M Lemoli, Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood 100(1), 230–237 (2002)CrossRef M. Ratta, F. Fagnoni, A. Curti, R. Vescovini, P. Sansoni, B. Oliviero, M. Fogli, E. Ferri, G. Robustelli Della Cuna, S. Tura, M. Baccarani, R.M Lemoli, Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood 100(1), 230–237 (2002)CrossRef
73.
Zurück zum Zitat M. Robertson-Tessi, A. El-Kareh, A. Goriely, A mathematical model of tumor-immune interactions. J. Theor. Biol. 294, 56–73 (2012)MathSciNetCrossRef M. Robertson-Tessi, A. El-Kareh, A. Goriely, A mathematical model of tumor-immune interactions. J. Theor. Biol. 294, 56–73 (2012)MathSciNetCrossRef
74.
Zurück zum Zitat S.E. Salmon, B.A. Smith, Immunoglobulin synthesis and total body tumor cell number in IgG multiple myeloma. J. Clin. Invest. 49, 1114–1121 (1970)CrossRef S.E. Salmon, B.A. Smith, Immunoglobulin synthesis and total body tumor cell number in IgG multiple myeloma. J. Clin. Invest. 49, 1114–1121 (1970)CrossRef
75.
Zurück zum Zitat H. Schättler, U. Ledzewicz, Optimal Control for Mathematical Models of Cancer Therapies (Springer, New York, 2015)CrossRef H. Schättler, U. Ledzewicz, Optimal Control for Mathematical Models of Cancer Therapies (Springer, New York, 2015)CrossRef
76.
Zurück zum Zitat A. Shanker, G. Verdeil, M. Buferne, E.-M. Inderberg-Suso, D. Puthier, F. Joly, C. Nguyen, L. Leserman, N. Auphan-Anezin, A.-M. Schmitt-Verhulst, CD8 T cell help for innate antitumor immunity. J. Immunol. 179(10), 6651–6662 (2007)CrossRef A. Shanker, G. Verdeil, M. Buferne, E.-M. Inderberg-Suso, D. Puthier, F. Joly, C. Nguyen, L. Leserman, N. Auphan-Anezin, A.-M. Schmitt-Verhulst, CD8 T cell help for innate antitumor immunity. J. Immunol. 179(10), 6651–6662 (2007)CrossRef
77.
Zurück zum Zitat A. Shanker, M. Buferne, A.-M. Schmitt-Verhulst, Cooperative action of CD8 T lymphocytes and natural killer cells controls tumour growth under conditions of restricted T-cell receptor diversity. Immunology 129(1), 41–54 (2010)CrossRef A. Shanker, M. Buferne, A.-M. Schmitt-Verhulst, Cooperative action of CD8 T lymphocytes and natural killer cells controls tumour growth under conditions of restricted T-cell receptor diversity. Immunology 129(1), 41–54 (2010)CrossRef
78.
Zurück zum Zitat E.M. Shevach, R.A. DiPaolo, J. Andersson, D.-M. Zhao, G.L. Stephens, A.M. Thornton, The lifestyle of naturally occurring CD4+ CD25+ Foxp3+ regulatory T cells. Immunol. Rev. 212(1), 60–73 (2006)CrossRef E.M. Shevach, R.A. DiPaolo, J. Andersson, D.-M. Zhao, G.L. Stephens, A.M. Thornton, The lifestyle of naturally occurring CD4+ CD25+ Foxp3+ regulatory T cells. Immunol. Rev. 212(1), 60–73 (2006)CrossRef
79.
Zurück zum Zitat D.R. Shook, D. Campana, Natural killer cell engineering for cellular therapy of cancer. Tissue Antigens 78(6), 409–415 2011.CrossRef D.R. Shook, D. Campana, Natural killer cell engineering for cellular therapy of cancer. Tissue Antigens 78(6), 409–415 2011.CrossRef
80.
Zurück zum Zitat R.L. Siegel, K.D. Miller, A. Jemal, Cancer statistics, 2016. CA: A Cancer J. Clin. 66, 7–30 (2016) R.L. Siegel, K.D. Miller, A. Jemal, Cancer statistics, 2016. CA: A Cancer J. Clin. 66, 7–30 (2016)
81.
Zurück zum Zitat M.J. Smyth, M.W.L. Teng, J. Swann, K. Kyparissoudis, D.I. Godfrey, Y. Hayakawa, CD4+ CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J. Immunol. 176(3), 1582–1587 (2006)CrossRef M.J. Smyth, M.W.L. Teng, J. Swann, K. Kyparissoudis, D.I. Godfrey, Y. Hayakawa, CD4+ CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J. Immunol. 176(3), 1582–1587 (2006)CrossRef
82.
Zurück zum Zitat D.K. Sojka, Y.-H. Huang, D.J. Fowell, Mechanisms of regulatory T-cell suppression - a diverse arsenal for a moving target. Immunology 124(1), 13–22 (2008)CrossRef D.K. Sojka, Y.-H. Huang, D.J. Fowell, Mechanisms of regulatory T-cell suppression - a diverse arsenal for a moving target. Immunology 124(1), 13–22 (2008)CrossRef
83.
Zurück zum Zitat E.D. Sontag, A dynamic model of immune responses to antigen presentation predicts different regions of tumor or pathogen elimination. Cell Syst. 4(2), 231–241 (2017)CrossRef E.D. Sontag, A dynamic model of immune responses to antigen presentation predicts different regions of tumor or pathogen elimination. Cell Syst. 4(2), 231–241 (2017)CrossRef
84.
Zurück zum Zitat N.V. Stepanova, Course of the immune reaction during the development of a malignant tumour. Biophysics 24, 917–923 (1980) N.V. Stepanova, Course of the immune reaction during the development of a malignant tumour. Biophysics 24, 917–923 (1980)
85.
Zurück zum Zitat H. Suen, R. Brown, S. Yang, C. Weatherburn, P.J. Ho, N. Woodland, N. Nassif, P. Barbaro, C. Bryant, D. Hart, J. Gibson, D. Joshua, Multiple myeloma causes clonal T-cell immunosenescence: identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade. Leukemia 30(8), 1716–1724 (2016)CrossRef H. Suen, R. Brown, S. Yang, C. Weatherburn, P.J. Ho, N. Woodland, N. Nassif, P. Barbaro, C. Bryant, D. Hart, J. Gibson, D. Joshua, Multiple myeloma causes clonal T-cell immunosenescence: identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade. Leukemia 30(8), 1716–1724 (2016)CrossRef
86.
Zurück zum Zitat P.W. Sullivan, S.E. Salmon, Kinetics of tumor growth and regression in IgG multiple myeloma. J. Clin. Invest. 51, 1697–1708 (1972)CrossRef P.W. Sullivan, S.E. Salmon, Kinetics of tumor growth and regression in IgG multiple myeloma. J. Clin. Invest. 51, 1697–1708 (1972)CrossRef
87.
Zurück zum Zitat C.M. Sungur, Y.J. Tang-Feldman, E. Ames, M. Alvarez, M. Chen, D.L. Longo, C. Pomeroy, W.J. Murphy, Murine natural killer cell licensing and regulation by T regulatory cells in viral responses. Proc. Natl. Acad. Sci. 110(18), 7401–7406 (2013)CrossRef C.M. Sungur, Y.J. Tang-Feldman, E. Ames, M. Alvarez, M. Chen, D.L. Longo, C. Pomeroy, W.J. Murphy, Murine natural killer cell licensing and regulation by T regulatory cells in viral responses. Proc. Natl. Acad. Sci. 110(18), 7401–7406 (2013)CrossRef
88.
Zurück zum Zitat G.W. Swan, T.L. Vincent, Optimal control analysis in the chemotherapy of IgG multiple myeloma. Bull. Math. Biol. 39(3), 317–337 (1977)CrossRef G.W. Swan, T.L. Vincent, Optimal control analysis in the chemotherapy of IgG multiple myeloma. Bull. Math. Biol. 39(3), 317–337 (1977)CrossRef
89.
Zurück zum Zitat M. Tang, R. Zhao, H. van de Velde, J.G. Tross, C. Mitsiades, S. Viselli, R. Neuwirth, D.-L. Esseltine, K. Anderson, I.M. Ghobrial, J.F. San Miguel, P.G. Richardson, M.H. Tomasson, F. Michor, Myeloma cell dynamics in response to treatment supports a model of hierarchical differentiation and clonal evolution. Clin. Cancer Res. 22(16), 4206–4214 (2016)CrossRef M. Tang, R. Zhao, H. van de Velde, J.G. Tross, C. Mitsiades, S. Viselli, R. Neuwirth, D.-L. Esseltine, K. Anderson, I.M. Ghobrial, J.F. San Miguel, P.G. Richardson, M.H. Tomasson, F. Michor, Myeloma cell dynamics in response to treatment supports a model of hierarchical differentiation and clonal evolution. Clin. Cancer Res. 22(16), 4206–4214 (2016)CrossRef
90.
Zurück zum Zitat D.Q. Tran, TGF-β: the sword, the wand, and the shield of FOXP3+ regulatory T cells. J. Mol. Cell Biol. 4(1), 29–37 (2012)CrossRef D.Q. Tran, TGF-β: the sword, the wand, and the shield of FOXP3+ regulatory T cells. J. Mol. Cell Biol. 4(1), 29–37 (2012)CrossRef
91.
Zurück zum Zitat S.W.M. Trisilowati, D.G Mallet, A cellular automata model to investigate immune cell-tumor cell interactions in growing tumors in two spatial dimensions, in Mathematical Models of Tumor-Immune System Dynamics, ed. by A. Eladaddi, P. Kim, D. Mallet. Springer Proceedings in Mathematics and Statistics, vol. 107 (Springer, New York, 2014), pp. 223–251 S.W.M. Trisilowati, D.G Mallet, A cellular automata model to investigate immune cell-tumor cell interactions in growing tumors in two spatial dimensions, in Mathematical Models of Tumor-Immune System Dynamics, ed. by A. Eladaddi, P. Kim, D. Mallet. Springer Proceedings in Mathematics and Statistics, vol. 107 (Springer, New York, 2014), pp. 223–251
92.
Zurück zum Zitat M. Vukmanovic-Stejic, Y. Zhang, J.E. Cook, J.M. Fletcher, A. McQuaid, J.E. Masters, M.H.A. Rustin, L.S. Taams, P.C.L. Beverley, D.C. Macallan, et al., Human CD4+ CD25hi Foxp3+ regulatory T cells are derived by rapid turnover of memory populations in vivo. J. Clin. Invest. 116(9), 2423 (2006)CrossRef M. Vukmanovic-Stejic, Y. Zhang, J.E. Cook, J.M. Fletcher, A. McQuaid, J.E. Masters, M.H.A. Rustin, L.S. Taams, P.C.L. Beverley, D.C. Macallan, et al., Human CD4+ CD25hi Foxp3+ regulatory T cells are derived by rapid turnover of memory populations in vivo. J. Clin. Invest. 116(9), 2423 (2006)CrossRef
93.
Zurück zum Zitat H.S. Warren, NK cell proliferation and inflammation. Immunol. Cell Biol. 74, 473–480 (1996)CrossRef H.S. Warren, NK cell proliferation and inflammation. Immunol. Cell Biol. 74, 473–480 (1996)CrossRef
94.
Zurück zum Zitat Y.-J. Wen, B. Barlogie, Q. Yi, Idiotype-specific cytotoxic t lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells. Blood 97(6), 1750–1755 (2001)CrossRef Y.-J. Wen, B. Barlogie, Q. Yi, Idiotype-specific cytotoxic t lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells. Blood 97(6), 1750–1755 (2001)CrossRef
95.
Zurück zum Zitat Y.-J. Wen, R. Min, G. Tricot, B. Barlogie, Q. Yi, Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy. Blood 99(9), 3280–3285 (2002)CrossRef Y.-J. Wen, R. Min, G. Tricot, B. Barlogie, Q. Yi, Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy. Blood 99(9), 3280–3285 (2002)CrossRef
96.
Zurück zum Zitat Y. Zhang, D.L. Wallace, C.M. De Lara, H. Ghattas, B. Asquith, A. Worth, G.E. Griffin, G.P. Taylor, D.F. Tough, P.C.L. Beverley, et al., In vivo kinetics of human natural killer cells: the effects of ageing and acute and chronic viral infection. Immunology 121(2), 258–265 (2007)CrossRef Y. Zhang, D.L. Wallace, C.M. De Lara, H. Ghattas, B. Asquith, A. Worth, G.E. Griffin, G.P. Taylor, D.F. Tough, P.C.L. Beverley, et al., In vivo kinetics of human natural killer cells: the effects of ageing and acute and chronic viral infection. Immunology 121(2), 258–265 (2007)CrossRef
Metadaten
Titel
A Mathematical Model for Tumor–Immune Dynamics in Multiple Myeloma
verfasst von
Jill Gallaher
Kamila Larripa
Urszula Ledzewicz
Marissa Renardy
Blerta Shtylla
Nessy Tania
Diana White
Karen Wood
Li Zhu
Chaitali Passey
Michael Robbins
Natalie Bezman
Suresh Shelat
Hearn Jay Cho
Helen Moore
Copyright-Jahr
2018
DOI
https://doi.org/10.1007/978-3-319-98083-6_5